Previous 10 | Next 10 |
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle a...
Brian Orelli, biotech contributor and writer at The Motley Fool, joins the channel to discuss why he owns Novocure (NASDAQ: NVCR) stock. Check out his reasoning in this video! *Stock prices used were the midday prices of Aug. 10, 2022. The video was published on Aug. 21, 2022....
Most investors like the idea of getting in early on an up-and-coming stock. But doing so isn't always easy. Sometimes what seems to be a rising star can crash and burn. We asked three Motley Fool contributors to pick monster stocks in the making to buy right now. Here's why they chose ...
After posting the worst first half of any year since 1970 (1), the stock market has come roaring back to life in Q3, with technology and risk bets leading the way following Fed Chair Jerome Powell’s signal at the July FOMC meeting of a possible shift in policy bearing. (2) The Fed beli...
Sen. Hassan toured the company’s U.S. headquarters in Portsmouth before meeting and speaking with employees On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure’s leadership team to tour the company’s U.S. headquarters in Portsmout...
Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...
After suffering the worst six months for stocks to start a year in more than half a century, investors received a bit of a reprieve in July. Some may be wondering if they missed the boat, and others may still be fearing the worst is yet to come for their portfolio. But the best course of ac...
NovoCure printed another successful quarter with upsides in revenue, but came in behind consensus below the bottom line. In particular, it made further inroads on its TTFields footprint, and this continues to be a key inflection point for the stock. Despite the constructive quarte...
Image source: The Motley Fool. Novocure (NASDAQ: NVCR) Q2 2022 Earnings Call Jul 28, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Novocure (NVCR) Q2 2022 Earnings Call Transcript
Novocure Ltd (NVCR) Q2 2022 Earnings Conference Call July 28, 2022, 08:00 ET Company Participants Ingrid Goldberg - VP, IR William Doyle - Executive Chairman Ashley Cordova - CFO Asaf Danziger - President, CEO & Director Uri Weinberg - Chief Science O...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...